대한뉴팜

The company had indirectly held shares of Caspian Sunrise Plc, a Kazakh oil field operator based in the United Kingdom, through Baverstock GmbH. However, as part of efforts to simplify its investment structure, the company is currently in the process of liquidating Baverstock GmbH, through which it has now come to directly hold 224,830,964 shares of Caspian Sunrise Plc.

Daehan New Pharm's Bio Research Center registered a patent on December 11 for a composition method of excipients that increase the storage period and survival rate of stem cells. Cell therapies achieve therapeutic effects by replacing damaged tissues/organs directly or through indirect actions via paracrine and endocrine factors, with ongoing research targeting various intractable diseases. Adult stem cells, especially adipose-derived mesenchymal stem cells, are advantageous due to ethical and safety benefits and ease of isolation with high cell yields. Unlike conventional drugs, cell therapies consist of living cells, resulting in a very short finished product shelf life of 1–2 days. Cell survival rates during transportation critically affect drug quality, directly limiting market competitiveness. To address these challenges, buffers to increase cell viability and rapid thawing methods post-freezing have been developed. However, toxicity and sterility issues related to commonly used DMSO freezing agents remain problematic. Daehan New Pharm developed a composition based on approved safe substances to extend storage duration and enhance cell survival rates for finished cell therapy products. Candidate substances including ascorbic acid, PDRN, pyridoxine, and DMEA wereed, and stem cell survival was evaluated over storage periods alongside analysis of post-storage stem cell characteristics. While single treatments of candidates had limited impact, a mixed composition containing ascorbic acid as the base with PDRN, pyridoxine, and DMEA significantly increased cell survival. Cell function was preserved even after more than three days of storage, as confirmed by flow cytometry and differentiation ability tests. This technology is expected to greatly extend the conventional 24-hour storage period during distribution in commercial stem cell therapies, enhancing product value and competitiveness. It is applicable not only to animal stem cells but also to human stem cells, with potential integration into various products. The Bio Research Center is dedicated to the efficient culturing, process development, transportation, and storage of stem cells, supporting the commercialization of stem cell therapies.

In 3Q 2020, Daehan New Pharm achieved a cumulative operating profit of 19.6 billion won with an operating margin of 17%, representing a 21% increase compared to the same period last year. Revenue grew 15% to 113.7 billion won, and net profit reached 6.3 billion won. The quarterly performance also showed growth momentum. Operating profit for 3Q rose 40% year-on-year to 7.4 billion won, while revenue increased 23% to 39.5 billion won. The growth was driven by a broad increase in product sales. The company launched "Fine S Tablet," a cold and allergic rhinitis medicine with bromelain as the main ingredient, and expanded sales of "Luthione Tablet," containing glutathione, well known for its use in whitening injections. Moreover, despite the challenges posed by the COVID-19 situation, the company has actively pursued research and development efforts. This overview reflects Daehan New Pharm’s strong financial performance and commitment to innovation during this period.

In the second quarter of 2020, Daehan New Pharm recorded cumulative sales of approximately 74.2 billion won, marking an 11.2% increase compared to the same period last year. Thanks to strengthened distribution management, portfolio enhancement, and consistent sales of existing key products, the company achieved an operating profit of 12.2 billion won, up 12.8% year-on-year, with an operating margin of 16.5%. Net profit also maintained a positive trend at 7.5 billion won, representing a net profit margin of 10.1%, compared to the same period last year. Steady profits were generated in the core areas of obesity and well-being pharmaceuticals, with the animal medicine business particularly driving sales growth. To sustain this momentum in the second half, the company has established detailed execution strategies by business division and is committed to strengthening its pipeline based on a new long-term vision to become a better company tomorrow.

Daehan New Pharm Co., Ltd. (054670) has promoted the license-in of internal and external deworming products for companion animals through a strategic partnership with the Irish pharmaceutical company Chanelle Pharma Group, established in 2018. As a result, in January 2020, the company launched ‘Fipnil Spot-On,’ an animal pharmaceutical product containing the active ingredient ‘Fipronil.’ Fipronil is a phenylpyrazole compound that, when applied directly to companion animals, binds to GABA receptors in the nervous system of external parasites such as fleas and ticks. It acts as an antagonist to chloride ion channels, causing hyperpolarization that leads to parasite death. When applied to the skin of the companion animal's shoulder blade area (between both shoulders), the product spreads over the body within 24 hours through the lipid-rich layer of the skin. It concentrates and is stored in sebaceous glands and hair follicles under the skin, maintaining its effect by being released through the skin and hair for more than a month. Based on the advanced technology of Chanelle Pharma Group that maximizes the action mechanism of Fipronil, ‘Fipnil Spot-On’ has demonstrated superior product efficacy through bioequivalence tests and comparisons with original products tested not only in the EU but also in multiple countries worldwide. According to the “Survey Report on Companion Animal Ownership and Public Awareness (2017)” by the Korea Pet Food Association, among 19.56 million households in Korea, 5.63 million (28.8%) own companion animals. The estimated number of companion dogs is about 6.6 million, and companion cats about 2.07 million. Companion animal ownership has increased roughly 57% over the past five years, and this trend is expected to continue due to factors such as nuclear family structure, an increase in single-person households, aging population, and higher income levels. Additionally, the rise in vector insects due to global warming and increased contact between companion animals and wildlife vectors pose ongoing challenges. Therefore, prevention through internal and external antiparasitic products for companion animals is essential to protect both animal and owner health. The domestic market for such products has grown to over 20 billion won. The head of Daehan New Pharm's animal pharmaceuticals division stated, “By supplying the competitively positioned ‘Fipnil Spot-On’ developed through strategic cooperation with Chanelle Pharma Group’s technology, we expect to become a leading player in the steadily growing domestic internal and external deworming market for companion animals.”

The vitamin D injection product 'Vita D Injection' was recognized for its stability and won the Formulation Technology Award at the 2019 International Conference of the Korean Pharmaceutical Society. The award-winning technology involves suppressing the formation of soft substances (degradants) in the vitamin D injection, securing its stability, and changing the storage temperature approval from 1–25℃ to 1–30℃. This improvement increases convenience in distribution and storage. Currently, Daehan New Pharm is the only company producing vitamin D injections under the 1–30℃ storage condition. Vitamin D, specifically calciferol, is classified into D2 (ergocalciferol) and D3 (cholecalciferol). D2 is made from ergosterol, a sterol, while D3 is produced in the skin upon sunlight exposure to 7-dehydrocholesterol. Vitamin D is known for promoting calcium absorption and is part of osteoporosis treatments. Recently, its deficiency has been linked to obesity, diabetes, and heart disease. Despite the growing importance of vitamin D, modern lifestyles with reduced outdoor activity and frequent use of sunscreen make deficiency common. Since vitamin D3 easily oxidizes to form unstable soft substances, developing vitamin D injections has been challenging. Daehan New Pharm secured stabilization technology that inhibits the formation of soft substances like trans-cholecalciferol. The company registered two related patents and successfully changed storage conditions to improve convenience. The domestic market for vitamin D injections grew from 12.3 billion won in 2017 to 13.2 billion won in 2018. Daehan New Pharm produces and sells three dosage forms of 'Vita D': 100,000 IU, 200,000 IU, and 300,000 IU.

In the third quarter of 2019, Daehan New Pharm recorded cumulative sales of 98.9 billion won, representing a 10% increase compared to the same period the previous year. Operating profit rose approximately 9% year-on-year to 16.1 billion won, with an operating margin of 16.3%. Net profit also significantly increased to 9.8 billion won, reflecting a net profit margin of 9.9%. The company is divided into four main business sectors: pharmaceutical, animal pharmaceuticals, overseas business, and bio business. The pharmaceutical division, which accounts for the largest share of sales, is further categorized into reimbursed drugs, non-reimbursed drugs, and obesity and well-being injections. In 2019, sales growth was driven by new reimbursed products. Expected sales of approximately 2 billion won are projected from three products: "Hyaleum injection" for joint pain, "Newpogrel SR" effective for chronic arterial occlusion, and "NPiren S," a gastric mucosal protector. The launch of "Fine S," known for its effects on fat decomposition and sleep quality improvement, laid the foundation for growth in 2020. The company is also expanding its well-being injection field based on the immune booster "Thymosin," launched in the second half of 2018, and the functional medicine injection "Same injection," approved for depression. Despite challenges from African swine fever and livestock market downturn, the animal pharmaceuticals division grew by over 10%, overcoming a 4% decline in the domestic market. High growth was achieved through the development of differentiated and functional new products, including large-scale swine growth promoters, an improved glutathione injection for stress relief in industrial animals, and differentiated mineral blocks stimulating digestion for Korean cattle. The company plans to launch new products in the companion animal pharmaceuticals market continuously from the first half of 2020 and is working on differentiated formulation research and licensing in of European finished products. In overseas business, Daehan New Pharm expects sales growth in 2020 through active promotion and marketing of its well-being and beauty-related products, showcased at the Manila and Indonesia Philbeauty fairs. Following successful exhibitions in Southeast Asia, the company plans to set up exhibitions and exclusive booths in the emerging Latin American market in the following year to actively promote its product excellence.

In the first half of 2019, Daehan New Pharm achieved sales of 66.8 billion won, marking an 8.6% increase compared to the same period the previous year. Operating profit rose 14.5% to 10.8 billion won, and net profit turned positive, reaching 6.6 billion won. Overall performance improved due to company-wide enhancements in sales efficiency and increased revenue from new product launches, while steady sales continued for existing key products. Steady profits were also generated in the core sectors of obesity and well-being pharmaceuticals, with strong sales expected in the second half of the year. The company plans to maximize performance through visionary management strategies and strengthening its new product portfolio. Financial structure improvements initiated last year and favorable reception of new products contributed to the improved results. The company aims to maintain operational efficiency and continue launching new products to sustain positive momentum throughout the second half.

Daehan New Pharm registered a patent for a method to specifically isolate heterogenetic fibroblasts with excellent skin regeneration effects by separating and culturing only those fibroblasts. Traditional therapies use fibroblasts primarily isolated from dermal tissue behind the ear for treating skin depressions, wrinkles, and refractory dermatitis. However, these treatments are based on mixed fibroblasts, resulting in lower efficacy compared to targeted therapies and cosmetic fillers. The patented method successfully isolates papillary dermal fibroblasts, located in specific dermal areas, known for high proliferative capacity and a central role in skin aging. Applying these in cell therapies is expected to show superior effects compared to conventional fibroblast treatments. The “High-purity isolation method for papillary dermal fibroblasts” uses transwell technology to separate highly active papillary dermal fibroblasts from mixed fibroblast populations. Cells isolated with this method showed about seven times higher levels of papillary dermal fibroblast factors and superior proliferative ability. This increase correlates with repeated culturing and maintaining processes. This purification technology for specific fibroblasts marks Daehan New Pharm's full-scale entry into the cell therapy market. According to Frost & Sullivan, the global cell therapy market is projected to grow at a CAGR of 9.4%, reaching $344 billion by 2021, while the domestic market is growing annually by 25%. Recently, the Bio Research Center relocated to Osong KBIO and is actively advancing biopharmaceutical development. They have developed a high-efficiency cell culture system for fibroblast therapies and are applying serum-free media from their Japanese partner CSTI in cell therapy development.